Statin-macrolide interaction risk: A population-based study throughout a general practice database

European Journal of Clinical Pharmacology

Volumn 61, Issue 8, 2005, Pages 615-620

  Piacentini, Nadia ^a   Trifiró, Gianluca ^a   Tari, Michele ^b   Moretti, Salvatore ^b   Arcoraci, Vincenzo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Caserta 1 Local Health Service   (Italy)

Author keywords

Concomitant prescription; General practitioners; Macrolide; Statin

Indexed keywords

ATORVASTATIN; CLARITHROMYCIN; ERYTHROMYCIN; FLUINDOSTATIN; FLURITHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JOSAMYCIN; MACROLIDE; MEVINOLIN; MIDECAMYCIN; MIOKAMYCIN; PRAVASTATIN; ROKITAMYCIN; ROXITHROMYCIN; SIMVASTATIN; TELITHROMYCIN;

ARTICLE; DATA BASE; DRUG SAFETY; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH SURVEY; HUMAN; MYOPATHY; PRESCRIPTION; PRIORITY JOURNAL; RISK;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DATABASES, FACTUAL; DRUG INTERACTIONS; FAMILY PRACTICE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; MACROLIDES; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; PRESCRIPTIONS, DRUG; RISK ASSESSMENT;

EID: 26244466388     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0972-z     Document Type: Article

References (28)

1. Castelli WP et al (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 256:2835-2838
2. Hebert PR et al (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomised trials. JAMA 278:313-321
3. Gotto AM, Grundy SM (1999) Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the Interdisciplinary Council on reducing the risk for coronary heart disease, 9th council meeting. Circulation 99:E1-E7
4. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J (2003) ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158
5. Bellosta S, Paoletti R, Corsini A (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109:III50-III57
6. Farmer JA, Torre-Amione G (2000) Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 108:351-352
7. Mahley RW, Bersot TP (2001) Drug therapy for hypercholesterolemia and dyslipidemia. In: Hardman JG, Limbird LE (eds) Goodman& Gilman's, the pharmacological basis of therapeutics, 10th edn. McGraw Hill, Medical Publishing Division, New York, pp 971-1002
8. Paoletti R, Corsini A, Bellosta S (2002) Pharmacological interactions of statins. Atheroscler 3:35-40
9. Corsini A et al (1999) New insights into the pharmacodynamics and pharmacokinetic properties of statins. Pharmacol Ther 84:413-428
10. Australian Adverse Drug Reactions Bulletin 23 (1), February 2004
11. Delaforge M et al (1988) Effects of roxithromycin on rat hepatic P 450 cytochromes: comparison with troleandomycin and erythromycin. Br J Clin Pract 42:67-69
12. Amacher DE et al (1991) Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicr Agents Chemother 35:1186-1190
13. Nahata M (1996) Drug interactions with azithromycin and the macrolides: an overview. J Antimicrob Chemother 37:133-142
14. Tinel M et al (1989) Effects of clarithromycin on cytochrome P450: comparison with other macrolides. J Pharm Exp Ther 250:746-751
15. Westphal JF (2000) Macrolides-induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50:285-295
16. Lawrenson R, Williams T, Farmer R (1999) Clinical information for research: the use of general practice databases. J Pub Health Med 21:299-304
17. Yang CC, Jick SS, Testa MA (2003) Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of co-morbidities and patient characteristics. Br J Clin Pharmacol 56:84-91
18. Heerey A, Barry M, Ryan M, Kelly A (2000) The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 169:176-179
19. Hansten PD (2003) Drug interaction management. Pharm World Sci 25(3):94-97
20. Herrlinger C, Klotz U (2001) Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroent 15:897-918
21. Delafuente JC (2003) Understanding and preventing drug interactions in elderly patients. Crit Rev One Hematol 48:133-143
22. Merlo J, Liedholm H et al (2001) Prescriptions with potential drugs interactions dispensed at Swedish pharmacies in January 1999: cross-sectional study. BMJ 323:427-428
23. "NOTA 13" of Italian Medicines Agency (AIFA) Available at website: http://www.ministerosalute.it/imgs/ C_17_bif_bollettino_25_file_itemName_4_filePdf.pdf. Accessed 16/05/2005
24. Cenedella RJ (2003) Beware of combining erythromycin with a statin. J Am Osteopath Assoc 103:117
25. Hueston WJ, Mainous AG 3rd, Ornstein S, Pan Q, Jenkins R (1999) Antibiotics for upper respiratory tract infections. Follow-up utilization and antibiotic use. Arch Fam Med 8:426-430
26. Maestre-Vera JR (2004) Treatment options in odontogenic infection. Med Oral Patol Oral Cir Bucal 9(Suppl 25-31):19-24
27. Saito M, Hirata-Koizumi M et al (2005) A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther 30:21-37
28. Committee on Safety of Medicines (2004) Curr Probl Pharmacovigilance 30:1-2